Table 1 Demographic characteristics
From: Societal preferences for adjuvant melanoma health states: UK and Australia
Characteristic | Overall (N = 155) | UK (n = 80) | Australia (n = 75) | p value |
|---|---|---|---|---|
Age (±SD) | 45.56 (±16.2) | 46.1 (±17.8) | 44.97 (±14.4) | 0.66 |
Male | 81 (52.3%) | 40 (50%) | 41 (54.7%) | 0.56 |
Race | 0.008 | |||
White | 120 (77.4%) | 65 (81.3%) | 55 (73.3%) | |
Black | 9 (5.8%) | 8 (10%) | 1 (1.3%) | |
Indian | 8 (5.2%) | 3 (3.8%) | 5 (6.7%) | |
Asian | 12 (7.7%) | 2 (2.5%) | 10 (13.3%) | |
Other/ multiracial | 5 (3.2%) | 2 (2.5%) | 4 (5.3%) | |
Employment | 0.005 | |||
Full time | 77 (49.7%) | 34 (42.5%) | 43 (57.3%) | |
Part time | 21 (13.5%) | 7 (8.8%) | 14 (18.7%) | |
Retired Student | 22 (14.2%) 14 (9%) | 15 (18.8%) 11 (13.8%) | 7 (9.3%) 3 (4.0%) | |
Other | 21 (13.5%) | 13 (16.4%) | 13 (10.6%) | |
Educationa | <0.001 | |||
Primary/junior/year 6 | 1 (0.6%) | 1 (1.3%) | 0 | |
Primary/third form/year 9 | 1 (0.6%) | 0 | 1 (1.3%) | |
Secondary/sixth form/year 13 | 51 (32.9%) | 39 (48.8%) | 12 (16%) | |
University/college | 80 (51.6%) | 33 (41.3%) | 47 (62.7%) | |
Postgraduate degree | 21 (13.5%) | 7 (8.8%) | 14 (18.7%) | |
Overall health | 0.016 | |||
Excellent | 31 (20%) | 12 (15.0%) | 19 (25.3%) | |
Very good | 60 (38.7%) | 26 (32.5%) | 34 (45.3%) | |
Good | 39 (25.2%) | 22 (27.5%) | 17 (22.7%) | |
Fair | 17 (11%) | 14 (17.5%) | 3 (4.0%) | |
Poor | 8 (5.2%) | 6 (7.5%) | 2 (2.7%) | |
Health conditions | ||||
None | 65 (41.9%) | 30 (37.5%) | 35 (46.7%) | 0.248b |
Arthritis | 24 (15.5%) | 16 (20%) | 8 (10.7%) | |
Heart disease | 5 (3.2%) | 5 (6.3%) | 0 | |
Depression | 22 (14.2%) | 15 (18.8%) | 7 (9.3%) | |
Diabetes | 6 (3.9%) | 4 (5%) | 2 (2.7%) | |
GI problems | 13 (8.4%) | 6 (7.5%) | 7 (9.3%) | |
Pain | 25 (16.1%) | 15 (18.8%) | 10 (13.3%) | |
Respiratory disorder | 23 (14.8%) | 18 (22.5%) | 5 (6.7%) | |
Other | 21 (13.5%) | 8 (10%) | 13 (17.3%) | |
Experience with melanomaa | <0.001c | |||
Been diagnosed with melanoma | 7 (4.5%) | 4 (5.0%) | 3 (4.0%) | |
Know someone with melanoma | 28 (18.1%) | 6 (7.5%) | 22 (29.3%) | |